Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18243718 | 0.76 | GABRA1 (0.44) | ALOX15LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL18243666 | 0.75 | ALOX5 (0.31) | ALDH1A1 | |
| SCHEMBL18243101 | 0.75 | MEN1 (0.46) | MEN1GAAKMT2AHSPA5SMN1; SMN2 | |
| SCHEMBL18378251 | 0.75 | MEN1 (0.46) | MEN1GAAKMT2AHSPA5SMN1; SMN2 | |
| SCHEMBL2994257 | 0.75 | MEN1 (0.46) | MEN1GAAKMT2AHSPA5ALDH1A1 | |
| SCHEMBL1264399 | 0.75 | MEN1 (0.46) | MEN1GAAKMT2AHSPA5SMN1; SMN2 | |
| SCHEMBL18242339 | 0.74 | ALDH1A1 (0.39) | MEN1GAAKMT2AALOX15ALOX12 | |
| SCHEMBL18244029 | 0.71 | HSPA5 (0.39) | MEN1GAAKMT2AHSPA5ALOX15 | |
| SCHEMBL18243560 | 0.70 | MEN1 (0.42) | MEN1GAAKMT2AHSPA5PTGS2 | |
| SCHEMBL18242817 | 0.68 | ALOX15 (0.34) | MEN1GAAKMT2AHSPA5ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10451967-B2 | Acid- and radical-generating agent and method for generating acid and radical | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2019-10-22 | — | — | US | disclosed |
| US-20160342084-A1 | ACID- AND RADICAL-GENERATING AGENT AND METHOD FOR GENERATING ACID AND RADICAL | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2016-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10451967-B2 | Acid- and radical-generating agent and method for generating acid and radical | CBR1, HAO2, CBR3 | MEN1 4766/4885GAA 2093/4885KMT2A 3389/4885 |
| US-20160342084-A1 | ACID- AND RADICAL-GENERATING AGENT AND METHOD FOR GENERATING ACID AND RADICAL | CBR1, HAO2, CBR3 | MEN1 4766/4885GAA 2093/4885KMT2A 3389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.